Corcept Therapeutics, Inc. (NASDAQ:CORT) Q4 2019 Earnings Conference Call February 20, 2020 5:00 PM ET Company Participants Gary Robb - CFO & Secretary Joseph Belanoff - Co-Founder, President, CEO & Director Andreas Grauer - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Tazeen Ahmad - Bank of America Merrill Lynch Edwin Zhang - Stifel, Nicolaus & Company Alan Leong - BioWatch Raymond Wu - Ladenburg Thalmann Jiale So ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Charlie Robb – Chief Financial Officer Joseph Belanoff – Chief Executive Officer Andreas Grauer – Chief Medical Officer Sean Maduck – Senior Vice President of Commercial Conference Call Participants Charles Duncan – Cantor Fitzgerald Adam Walsh – Stifel Chris Howerton – Jefferies Matt Kaplan – Thalmann Sean Kang – H.C. Wainwright Alan Leong – BioWatch News Operator Good day, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ________________ ...

Corcept Therapeutics Inc. (NASDAQ:CORT) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Charlie Robb - CFO Joseph Belanoff - CEO Andreas Grauer - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Matt Kaplan - Ladenburg Thalmann Neil Carnahan - Stifel Operator Good day, and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. [Operator Instructions] At this time, I would like to turn the conference over to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 _____________________ ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Charlie Robb - Chief Financial Officer Joseph Belanoff - Chief Executive Officer Andreas Grauer - Chief Medical Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Neil Carnahan - Stifel Operator Good day everyone and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator Instructions]. At this time, I would like to tur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ____________________ ...

Corcept Therapeutics Inc. (NASDAQ:CORT) Q4 2018 Earnings Conference Call February 25, 2019 5:00 PM ET Company Participants Charlie Robb - CFO Dr. Joseph Belanoff - CEO Conference Call Participants Adam Walsh - Stifel David Buck - B. Riley FBR Peter Stapor - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Alan Leong - BioWatch News Operator Good day everyone and welcome to the Corcept Therapeutics Conference Call. Today's call is being recorded. [Operator Instructions] At this time, I would like to turn t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...